Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
Memorial Sloan Kettering Cancer Center · Cornell University · +18 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
468
total citations
- FWCI
- 39.56
- Percentile
- 100%
- References
- 14
Citations per year
Authors
23Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Clinical endpoint
- Evening
- Internal medicine
- Surgery
- Surrogate endpoint
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- FFFoundation for the National Institutes of Health
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizerAward: P30 CA008748
- MSMemorial Sloan-Kettering Cancer CenterAward: CA008748
- KTKaryopharm Therapeutics
- EExelixisAward: P30 CA008748
- SOSociety of Memorial Sloan Kettering
- CTCelldex Therapeutics
- FPFive Prime Therapeutics
- IIncyte
- DDaiichi-Sankyo
- EEisaiAward: P30 CA008748
- IOIstituto Ortopedico Rizzoli di Bologna
- PPharmaMar
- PPlexxikon
- NINational Institutes of HealthAwards: P30 CA008748, 30 CA008748
- GGenentechAward: P30 CA008748
- ESEMD Serono
- IIgnyta
- DSDaiichi Sankyo Company
- NCNational Cancer InstituteAwards: CA008748, P30 CA008748
- DSDaiichi Sankyo Europe